NEW YORK, Jan 22 (Reuters) - Chelsea Therapeutics International Ltd. (CHTP.O: Quote, Profile , Research) said on Monday U.S. regulators granted orphan drug status to its experimental drug Droxidopa for treating a neurological disorder that can cause drops in blood pressure.
